Aeglea Biotherapeutics Inc. (AGLE) Upgraded by Zacks Investment Research to Hold
According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
Aeglea Biotherapeutics (NASDAQ:AGLE) opened at 6.90 on Tuesday. The firm’s market capitalization is $92.54 million. Aeglea Biotherapeutics has a 1-year low of $3.89 and a 1-year high of $12.75. The stock’s 50 day moving average is $6.67 and its 200-day moving average is $6.59.
Aeglea Biotherapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Equities research analysts forecast that Aeglea Biotherapeutics will post ($4.77) EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in the stock. Ghost Tree Capital LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $243,000. Perceptive Advisors LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $515,000. Finally, VHCP Management II LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $1,527,000. 40.71% of the stock is owned by institutional investors.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Stock Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.